Alkermes Plc
NASDAQ:ALKS
Alkermes Plc
NASDAQ:ALKS
Price:
33.245
USD
-0.14%
Market Closed
Market Cap:
$5.5B
Relative Value
The Relative Value of one
ALKS
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 33.245 USD,
Alkermes Plc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALKS Relative Value
HIDDEN
Multiples Across Competitors
ALKS Competitors Multiples
Alkermes Plc Competitors
Alkermes Plc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IE |
|
Alkermes Plc
NASDAQ:ALKS
|
5.5B USD | 3.6 | 16.2 | 11.3 | 12.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD | 6.9 | 174.4 | 16.8 | 23.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD | 6.6 | 23.8 | 16.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD | 10.6 | 33.9 | 25 | 26.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD | 5.9 | 18.7 | 14.2 | 16.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
72.7B AUD | 3.2 | 16.8 | 11.5 | 14.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR | 14.4 | 33.9 | 57.9 | 59.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
